Q-omics provides the consensus-scored ANAPC1P4 profile across patient tissues and cancer cell-line models. ANAPC1P4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANAPC1P4 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ANAPC1P4 RNA expression shows 18,582 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where ANAPC1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC1P4 survival associations across molecular data types. ANAPC1P4 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC1P4 RNA expression–survival associations across cancer types. High ANAPC1P4 expression shows unfavorable associations in MESO, ACC, UVM, CESC, BRCA and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANAPC1P4 RNA expression.
This table summarizes ANAPC1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANAPC1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC1P4 shows higher tumor expression in KIRC, HNSC, COAD, KIRP, STAD and BRCA. The KIRC box plot shows higher ANAPC1P4 RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with ANAPC1P4 in patient tissues and cancer cell lines. In patient samples, ANAPC1P4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANAPC1P4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
